Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-3329
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure ; volume:9 ; number:1 ; day:15 ; month:1 ; year:2019 ; pages:1-7 ; date:12.2019
Clinical Sarcoma Research ; 9, Heft 1 (15.1.2019), 1-7, 12.2019
- Urheber
-
Savani, Malvi
Murugan, Paari
Skubitz, Keith M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13569-018-0111-0
- URN
-
urn:nbn:de:101:1-2019021012443152624824
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 09:00 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Savani, Malvi
- Murugan, Paari
- Skubitz, Keith M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer